Bioavailability of dextromethorphan (as dextrorphan) from sustained release formulations in the presence of guaifenesin in human volunteers

Physiologically based pharmacokinetic (PBPK) modeling of the role of CYP2D6 polymorphism for metabolic phenotyping with dextromethorphan

“…Information on metabolizer phenotype (UM, EM, IM, PM) is provided where reported. Data from ( Capon et al, 1996 ; Köhler et al, 1997 ; Demirbas et al, 1998 ; Tennezé et al, 1999 ; Zawertailo et al, 2010 ; Hu et al, 2011 ; Yamazaki et al, 2017 ).…”

Physiologically based pharmacokinetic (PBPK) modeling of the role of CYP2D6 polymorphism for metabolic phenotyping with dextromethorphan

“…Information on metabolizer phenotype (UM, EM, IM, PM) is provided where reported. Data from (Capon et al, 1996; Demirbas et al, 1998; Hu et al, 2011; Köhler et al, 1997; Tennezé et al, 1999; Yamazaki et al, 2017; Zawertailo et al, 2010).…”

A Single-Dose, Three-Period, Six-Sequence Crossover Study Comparing the Bioavailability Study of Dextromethorphan Hydrobromide Sustained Release (SR) Tablet and the Immediate Release (IR) Tablet in Healthy Volunteers Under Fasting Condition

“…Several studies on dextromethorphan have been stated (Silvati et al, 1987;Silvasti et al, 1990;Woodworth et al, 1987a;Demirbas et al, 1998;Ramachander et al, 1977), all these studies have carried out in combination drug, none of these studies have carried out to demonstrate the once daily dosage of dextromethorphan in healthy volunteers.…”